Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Balchem (BCPC) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Balchem (BCPC) over the last 16 years, with Q3 2025 value amounting to $65.1 million.

  • Balchem's Cash & Equivalents fell 1167.12% to $65.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.1 million, marking a year-over-year decrease of 1167.12%. This contributed to the annual value of $49.5 million for FY2024, which is 2316.94% down from last year.
  • As of Q3 2025, Balchem's Cash & Equivalents stood at $65.1 million, which was down 1167.12% from $65.4 million recorded in Q2 2025.
  • Over the past 5 years, Balchem's Cash & Equivalents peaked at $103.2 million during Q4 2021, and registered a low of $49.5 million during Q4 2024.
  • In the last 5 years, Balchem's Cash & Equivalents had a median value of $65.4 million in 2025 and averaged $69.6 million.
  • As far as peak fluctuations go, Balchem's Cash & Equivalents plummeted by 3724.35% in 2022, and later skyrocketed by 3622.48% in 2023.
  • Balchem's Cash & Equivalents (Quarter) stood at $103.2 million in 2021, then plummeted by 35.53% to $66.6 million in 2022, then fell by 3.17% to $64.4 million in 2023, then fell by 23.17% to $49.5 million in 2024, then soared by 31.46% to $65.1 million in 2025.
  • Its Cash & Equivalents was $65.1 million in Q3 2025, compared to $65.4 million in Q2 2025 and $49.9 million in Q1 2025.